Stay updated with breaking news from Forensic drug. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mike Minor and Debra Nichols Join The IMA Group as Executives in Clinical Research Posted May 19, 2021
Tarrytown, NY – May 19, 2021 –The IMA Group announced today the ongoing expansion of its Clinical Research Division through the addition of two industry veterans with over 65 years of combined clinical, operational, commercial, strategic and scientific experience. IMA Clinical Research is a physician-founded network of 10 integrated clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas. With access to 80 additional, broadly distributed medical offices of The IMA Group, IMA Clinical Research has extensive capabilities to conduct site-based, hybrid and decentralized clinical trials that support the development of safe and effective therapies. The Clinical Research Division offers access to new advances in pharmacology and biotechnology for research subjects, as well as a robust database of interested clinical trial participants for pharmaceutical sponsors.
Mike Minor and Debra Nichols Join The IMA Group as Executives in Clinical Research prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
AiCure and The IMA Group Partner to Optimize Clinical Trial Recruitment and Patient Engagement IMA Clinical Research, a division of The IMA Group, will equip patients with AiCure's patient engagement solution to observe health management in a non-trial setting, advancing future trial recruitment criteria News provided by Share this article NEW YORK, March 15, 2021 /PRNewswire/ -- AiCure, an AI and data analytics company focused on improving clinical trials, and IMA, a national leader in providing clinical evaluation and research services, today announced a partnership to gain a widespread understanding of patient behavior and drug compliance outside of a clinical trial setting. With a database of over 300,000 potential subjects, IMA will roll out AiCure's patient engagement solution, Patient Connect, to study participants, offering patients convenient and enhanced support to successfully manage their existing treatment at home. This data will ultimately give sponsors access to a diverse pool of patients with known adherence patterns across therapeutic areas that could be recruited for upcoming trials, improving the likelihood of a trial's success and collection of high-quality data.
Integrated Analyses Tackle the Rise Of "Legal Highs" news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
The IMA Group Acquires EVOnational, an IME Services Provider Share Article Latest acquisition adds 7,000 providers to IMA’s network and further expands its scope Mark Weinberger, Ph.D., MPH, president of The IMA Group, today announced the company's acquisition of EVOnational. "EVOnational brings our company the services, programs and people to ideally enhance and complement what we already offer our clients,” said IMA’s President Mark Weinberger, Ph.D., MPH TARRYTOWN, N.Y. (PRWEB) February 23, 2021 The IMA Group (IMA) announced today it has acquired EVOnational, a national provider of independent medical exams (IMEs), medical screenings and other evaluations. The acquisition extends IMA’s scope and capabilities while enhancing its national offering of behavioral and medical evaluations. The company serves the workers’ compensation, liability, disability and auto markets.